Exelixis, Inc. (NASDAQ:EXEL) Director Sells $461,112.05 in Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Alan M. Garber sold 19,205 shares of the business’s stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $24.01, for a total value of $461,112.05. Following the completion of the sale, the director now directly owns 35,703 shares of the company’s stock, valued at approximately $857,229.03. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Exelixis Price Performance

Shares of NASDAQ:EXEL opened at $23.86 on Thursday. The business’s fifty day moving average price is $21.99 and its two-hundred day moving average price is $21.97. Exelixis, Inc. has a fifty-two week low of $18.08 and a fifty-two week high of $24.34. The stock has a market capitalization of $7.23 billion, a price-to-earnings ratio of 37.28, a price-to-earnings-growth ratio of 0.62 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.02. The firm had revenue of $479.65 million for the quarter, compared to analysts’ expectations of $481.23 million. Exelixis had a return on equity of 8.57% and a net margin of 11.35%. Research analysts expect that Exelixis, Inc. will post 1.22 EPS for the current fiscal year.

Institutional Trading of Exelixis

Several large investors have recently made changes to their positions in the business. Stifel Financial Corp grew its holdings in shares of Exelixis by 3.0% during the third quarter. Stifel Financial Corp now owns 17,330 shares of the biotechnology company’s stock worth $379,000 after purchasing an additional 506 shares during the last quarter. Alaska Permanent Fund Corp grew its holdings in shares of Exelixis by 1.5% during the third quarter. Alaska Permanent Fund Corp now owns 40,855 shares of the biotechnology company’s stock worth $893,000 after purchasing an additional 596 shares during the last quarter. Fifth Third Bancorp grew its holdings in shares of Exelixis by 44.2% during the third quarter. Fifth Third Bancorp now owns 1,970 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 604 shares during the last quarter. Panagora Asset Management Inc. lifted its stake in shares of Exelixis by 3.4% during the fourth quarter. Panagora Asset Management Inc. now owns 19,892 shares of the biotechnology company’s stock valued at $319,000 after acquiring an additional 662 shares during the period. Finally, Signaturefd LLC lifted its stake in shares of Exelixis by 17.1% during the third quarter. Signaturefd LLC now owns 4,577 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 668 shares during the period. Institutional investors own 85.27% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Stifel Nicolaus boosted their target price on Exelixis from $23.00 to $25.00 and gave the stock a “hold” rating in a report on Friday, February 2nd. Royal Bank of Canada boosted their target price on Exelixis from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. BTIG Research assumed coverage on Exelixis in a report on Tuesday, December 19th. They issued a “buy” rating and a $27.00 target price for the company. Citigroup assumed coverage on Exelixis in a report on Friday, December 15th. They issued a “buy” rating and a $31.00 target price for the company. Finally, TheStreet upgraded Exelixis from a “c+” rating to a “b-” rating in a report on Monday, March 18th. Five research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $26.29.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.